REMINDER: Our user survey closes on Friday, please submit your responses here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Share News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EXECUTIVE CHANGES: Rosslyn promotes new CEO; Celtic CEO ready to start

Tue, 06th Apr 2021 14:54

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Tuesday and not separately reported by Alliance News:

----------

GlaxoSmithKline PLC - Brentford, Middlesex-based pharmaceutical firm - Hires Anne Beal as non-executive director, starting May 6. Beal will replace Lynn Elsenhans as chair of the Corporate Responsibility Committee, and Elsenhans will stay on the board for an additional year to allow for a handover. Beal is founder and chief executive officer of AbsoluteJOI Skincare. She spent six years at Harvard Medical School and Massachusetts General Hospital, instructing in paediatrics.

----------

Assura PLC - Warrington, England-based primary care property investor - Jenefer Greenwood will retire as non-executive director at Assura's July 6 annual general meeting. Hires Emma Cariaga, Noel Gordon and Sam Barrell as new non-executive directors, starting on May 1. Cariaga is joint head of Canada Water Development on the executive committee of British Land Co PLC. Gordon was global managing director at consultants Accenture. For the UK National Health Service, he was chair of NHS Digital and a non-executive director of NHS England. Barrell is chief operating officer of the Crick Institute, which supports biomedical research.

----------

Rosslyn Data Technologies PLC - London-based cloud enterprise data analytics platform - Chief Executive Officer Roger Bullen steps down from board, effective immediately, but will remain as an adviser for six months. Bullen served for five years as CEO and chief financial officer. Chief Customer Officer Paul Watts is promoted to CEO. Watts joined Rosslyn back in August and before that was CEO of Blue Prism KK Japan, a robotic process automation company. Both Chair James Appleby and CFO Ash Mehta will take on additional responsibilities. Rosslyn also says it expects its results for the financial year ending April 30 to be in line with market expectations. It will issue a trading update in late May.

----------

Celtic PLC - Glasgow football club - Confirms that Dominic McKay will join Celtic on April 19 before replacing retiring Peter Lawwell as chief executive on July 1. Scottish Rugby confirmed that McKay will leave as chief operating officer on April 16, following a successful handover. McKay, who also was chair of the Guinness Pro14 annual rugby union competition, will join the Celtic board.

----------

Amryt Pharma PLC - London-based biopharmaceutical firm focused on rare and orphan diseases - Hires Sheila Frame as president for the Americas. Frame has held senior positions at Novartis AG, Bristol-Myers Squibb Co and AstraZeneca PLC.

----------

MyHealthChecked PLC - Cardiff-based consumer home-testing healthcare - Peter Dines steps down as non-executive director on Tuesday. Dines is chief operating officer of Mercia Asset Management PLC, whose funds have a 28% stake in MyHealthChecked. He is standing down to focus on other portfolio companies.

----------

Northamber PLC - Chessington, Surrey-based audio-visual and information technology distributor - Promotes Finance Director Tony Lee to board and hires Riccardo Reggio as a non-executive director, both from last Thursday. Lee re-joined Northamber in August of last year, having previously been finance director from 2003 to 2005. Reggio is a corporate strategy and acquisitions adviser who worked at Monitor Group for 15 years.

----------

By Tom Waite; thomaslwaite@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
8 May 2018 13:13

Former Amryt Pharma Non-Executive Friel Sells 8.4 Million Shares (ALLISS)

LONDON (Alliance News) - Amryt Pharma PLC on Tuesday said on Tuesday a company owned by a former non-executive director has sold 8.4 million shares in the company.Raglan Road Capital Ltd is

Read more
15 Mar 2018 14:15

Amryt 2017 Revenue Soars On Lojuxta Sales As New In-Licence Sealed

LONDON (Alliance News) - Amryt Pharma PLC said Thursday it has signed an in-licence agreement for a gene therapy platform, with the company making a "very start in for to

Read more
15 Mar 2018 05:25

UK Stocks-Factors to watch on March 15

March 15 (Reuters) - Britain's FTSE 100 index is seen opening 2 points higher at 7,135 on Thursday, according to financial bookmakers. * SHELL: Royal Dutch Shell is close to

Read more
8 Mar 2018 15:39

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 9 March SIGFull Year ResultsInmarsatFull Year ResultsGVC Year 12

Read more
6 Feb 2017 09:23

Amryt Pharma Gets Positive Study Results For Possible Acromegaly Drug

Read more
2 Dec 2016 08:07

Amryt Pharma secures €20m loan from European Investment Bank

(ShareCast News) - AIM-listed Amryt Pharma has secured a €20m loan from the European Investment Bank to secure its near and mid-term funding for its gel product and a development for a drug compound compound. The loan secures funding for its product Episalvan, which treats skin disorder Epidermolysi

Read more
7 Nov 2016 12:19

Amryt Pharma's drug compound gains FDA approval

(ShareCast News) - The US Food and Drug Administration (FDA) has granted orphan drug designation to AIM-listed Amryt Pharma's drug compound which has the potential to treat acromegaly. The drug compound, AP102, now qualifies for tax credits for qualified clinical trials and market exclusivity on reg

Read more
13 Sep 2016 16:10

Amryt Pharma positive about drug developments

(ShareCast News) - Clinical stage specialty pharma company focused on best in class treatments for orphan diseases, Amryt Pharma, posted its interim financial statements for the six months to 30 June on Tuesday. The AIM-traded firm was admitted to trading on AIM and the ESM market of the Irish Stock

Read more
9 Jun 2016 09:55

Amryt Pharma Plans Trials Of Episalvan Product By End Of 2016

Read more
19 Apr 2016 12:05

Amryt Pharma reverses onto AIM to advance orphan drug strategy

(ShareCast News) - Speciality drug developer Amryt Pharma has completed its flotation via the reverse takeover of AIM-listed Fastnet, raising £10m of new cash in the process and acquiring two operating companies. As part of the float, Amryt acquired drug German drug development and manufacturing com

Read more
19 Apr 2016 08:52

Amryt Pharma Starts Trading After Fastnet Reverse Takeover (ALLIPO)

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.